Scarica l'app Stockscreener
1.84
6.60%
-0.13
Pre-mercato:
1.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.97
Aprire:
$1.98
Volume 24 ore:
732.34K
Relative Volume:
2.50
Capitalizzazione di mercato:
$66.15M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.6727
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
+3.95%
1M Prestazione:
+8.88%
6M Prestazione:
-4.17%
1 anno Prestazione:
+42.64%
Intervallo 1D:
$1.825
$2.07
Intervallo di 1 settimana:
$1.65
$2.07
Portata 52W:
$0.95
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.84 | 63.63M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gain Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Fed Impact & Precise Buy Zone Tips - Newser
Visual trend scoring systems applied to Gain Therapeutics Inc.July 2025 Action & Long-Term Growth Stock Strategies - Newser
Is Gain Therapeutics Inc. showing signs of accumulationJuly 2025 Trade Ideas & Daily Stock Momentum Reports - Newser
Key resistance and support levels for Gain Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - Newser
Chart overlay techniques for tracking Gain Therapeutics Inc.Trade Performance Summary & Precise Buy Zone Tips - Newser
Best data tools to analyze Gain Therapeutics Inc. stockShort Setup & Daily Oversold Stock Bounce Ideas - Newser
Chart based exit strategy for Gain Therapeutics Inc.2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
What the charts say about Gain Therapeutics Inc. todayEarnings Beat & Technical Entry and Exit Alerts - Newser
Real time alert setup for Gain Therapeutics Inc. performanceWeekly Loss Report & Verified Momentum Stock Ideas - Newser
Is This a Bottoming Phase for Gain Therapeutics Inc.Market Risk Analysis & Weekly Market Pulse Alerts - classian.co.kr
Is Gain Therapeutics Inc. forming a reversal patternBond Market & Short-Term Trading Opportunity Alerts - Newser
Short interest data insights for Gain Therapeutics Inc.July 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Gain Therapeutics shares rise 5.20% intraday after BioXcel Therapeutics announces positive FDA Pre-sNDA. - AInvest
Gain Therapeutics Stock Soars 10.4% on Innovation Push - AInvest
Will Gain Therapeutics Inc. benefit from seasonality2025 Volatility Report & Free Real-Time Volume Trigger Notifications - 선데이타임즈
Why Gain Therapeutics Inc. stock attracts strong analyst attentionQuarterly Trade Report & Comprehensive Market Scan Insights - Newser
Candlestick signals on Gain Therapeutics Inc. stock todayWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - Newser
Has Gain Therapeutics Inc. found a price floorQuarterly Profit Summary & Weekly High Conviction Ideas - Newser
Chartists See Breakout Potential in Gain Therapeutics Inc.Quarterly Profit Summary & Weekly Chart Analysis and Trade Guides - beatles.ru
Chart Analysts Warn of Resistance Near Gain Therapeutics Inc. PriceJuly 2025 EndofMonth & Stock Portfolio Risk Control - metal.it
Using data models to predict Gain Therapeutics Inc. stock movementM&A Rumor & AI Enhanced Market Trend Forecasts - Newser
Published on: 2025-08-16 10:33:24 - sundaytimes.kr
Short Term Trend Reversal in Gain Therapeutics Inc. Possible2025 Trading Volume Trends & Smart Money Movement Alerts - beatles.ru
Using flow based indicators on Gain Therapeutics Inc.July 2025 Summary & Scalable Portfolio Growth Methods - Newser
Buy Recommendation for Gain Therapeutics Based on Parkinson's Drug Development and Strong Financial Position - AInvest
Gain Therapeutics (NASDAQ:GANX) Given New $6.00 Price Target at Roth Capital - Defense World
Gain Therapeutics, Inc. shares rise 3.27% intraday after Perspective Therapeutics presented positive [212Pb]VMT-α-NET study update at ASCO Annual Meeting. - AInvest
Intraday Charts Show Spike in Gain Therapeutics Inc. ActivityBond Market & Smart Swing Trading Alerts - sundaytimes.kr
What analysts say about Gain Therapeutics Inc. stock outlookMarket Activity Report & Daily Profit Focused Screening - Newser
What analysts say about Gain Therapeutics Inc. stock outlook [2025 Market Sentiment]High Accuracy Investment Signals - Newser
Gain Therapeutics Inc.’s Price Action Aligns with Quant SignalsReal-Time Analysis With Entry Targets In Progress - 선데이타임즈
Gain Therapeutics completes Q2 2025 with Phase 1b enrolment, $7.1mln in net proceeds. - AInvest
Gain Therapeutics Reports Financial Results for Second Quarter 2025 - TradingView
Gain Therapeutics, Inc. shares rise 4.11% intraday after Aardvark Therapeutics reports positive ARD-201 preclinical results. - AInvest
Gain Therapeutics reports Q2 EPS (19c), consensus (17c) - TipRanks
Gain Therapeutics Fast-Tracks Parkinson's Drug Trial: Key Results Coming Q4 2025, Raises $7.1M - Stock Titan
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):